Keyphrases
3-group
33%
Anti-PD-1
33%
Anti-PD-1 Antibody
33%
Antitumor Efficacy
33%
Antitumor Immune Response
33%
Checkpoint Inhibition
33%
Cisplatin
100%
Cisplatin Sensitivity
100%
Combination Therapy
33%
DNA Damage
33%
Efflux
33%
Extracellular Vesicles
66%
Flow Cytometry
33%
Gene Ontology
33%
Herpes Simplex Virus
33%
Immune Checkpoint Therapy
66%
Infected Cells
66%
Inflammatory Response
33%
Innate Immune Cells
33%
Metastatic Mouse Model
33%
Micronucleus
66%
Oncolytic Herpes Simplex Virus (oHSV)
100%
Ovarian Cancer
33%
Path Analysis
33%
PD-1 Immune Checkpoint
33%
Platinum Resistance
33%
Platinum-resistant Ovarian Cancer
66%
Programmed Death-ligand 1 (PD-L1)
33%
Reduced Expression
33%
Related Pathway
33%
RNA Sequencing (RNA-seq)
33%
Splenocytes
33%
Therapeutic Efficacy
33%
Tumor
33%
Tumor Cells
33%
Tumor Immunity
100%
Vesicle Trafficking
100%
Virus Therapy
100%
Immunology and Microbiology
Gene Ontology
33%
Herpes Simplex Virus
33%
Immune Response
33%
Immunocompetent Cell
33%
Immunotherapy
33%
Inflammation Response
33%
Micronucleus
66%
Mouse
100%
Mouse Model
33%
Oncolytic Herpes Virus
100%
Programmed Death-Ligand 1
33%
RNA Sequence
33%
Splenocyte
33%
Tumor Cell
33%
Virotherapy
100%
Medicine and Dentistry
Cisplatin
100%
Combination Therapy
40%
Effusion
20%
Flow Cytometry
20%
Herpes Simplex Virus
20%
Immune Response
20%
Immunocompetent Cell
20%
Immunotherapy
20%
Micronucleus
40%
Neoplasm
20%
Oncolytic Herpes Virus
100%
Ovarian Cancer
20%
Platinum-Resistant Ovarian Cancer
40%
Programmed Death-Ligand 1
20%
RNA Sequence
20%
Serositis
20%
Tumor Cell
20%
Virotherapy
100%
Pharmacology, Toxicology and Pharmaceutical Science
Cisplatin
100%
Combination Therapy
40%
Effusion
20%
Flow Cytometry
20%
Herpes Simplex Virus
20%
Immunotherapy
20%
Inflammation
20%
Mouse
60%
Mouse Model
20%
Neoplasm
40%
Oncolytic Herpes Virus
100%
Ovary Cancer
60%
RNA-Sequencing
20%
Virotherapy
100%